Fig. 5.

Relationship between percentage change in soluble VEGFR-2 level from baseline to cycle 2 day 1 and AUC₁₂ in Studies 1 and 2 (pooled data): n = 13—five patients were excluded (two discontinued treatment before cycle 2 day 1; two had axitinib dose titrated before cycle 2 day 1; and one did not receive cycle 1 day 14 am dose). AUC ₁₂ area under the plasma concentration–time curve from time zero to 12 h; VEGFR-2 vascular endothelial growth factor receptor-2